about
Chemotherapy for resistant or recurrent gestational trophoblastic neoplasiaProphylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasiaCombination chemotherapy for primary treatment of high-risk gestational trophoblastic tumourFirst-line chemotherapy in low-risk gestational trophoblastic neoplasiaChemotherapy for resistant or recurrent gestational trophoblastic neoplasiaChemotherapy for resistant or recurrent gestational trophoblastic neoplasiaCombination chemotherapy for high-risk gestational trophoblastic tumourFirst line chemotherapy in low risk gestational trophoblastic neoplasiaProphylactic chemotherapy for hydatidiform moleFirst line chemotherapy in low risk gestational trophoblastic neoplasiaCombination chemotherapy for high-risk gestational trophoblastic tumourTreatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancyCurable metastatic cancer in young women.Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapyCellular immune response levels in gestational trophoblastic tumor patients after hydatidiform mole.Computer system for assisting with clinical interpretation of tumour marker data.Determination of tumor markers in serum. Pitfalls and good practice.Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case reportThe management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).Treating gestational trophoblastic disease.Progress in gynecologic cancer detection and treatment.Gestational trophoblastic disease: a multimodality imaging approach with impact on diagnosis and management.Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours.Lessons from choriocarcinoma.The role of surgery and radiation therapy in the management of gestational trophoblastic disease.Gestational trophoblastic neoplasia, FIGO 2000 staging and classification.Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study.Current chemotherapeutic management of patients with gestational trophoblastic neoplasiaUterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia.Long-term effects of chemotherapy on lymphocyte chromosomes from patients treated for gestational trophoblastic tumoursCompeting risks determining event-free survival in early breast cancer.Activity of high-dose cis-platinum (NCI 119875) in combination with vincristine and methotrexate in drug-resistant gestational choriocarcinoma. A report of 17 cases.Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours.Marker proteins as indicators of tumour response to therapy.Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia (GTN) be simplified? A new retrospective analysis from a nationwide data-set.Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia.The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours.
P2860
Q24186495-2414CF4A-E420-4CE2-B208-9F5E88477251Q24198138-5C411F6E-C70D-4FC4-BB42-F08F890808A0Q24201759-06A0CD3C-B962-4719-AC6B-29EF50353316Q24202155-560DCBEB-0FA1-488C-8E29-9F39FB07819EQ24202503-74F43725-DF6C-46AF-BC58-BDFA64A64BF4Q24235967-0DA0CDF9-3C12-417A-B74A-B125D8F34BF6Q24241850-59C9E923-EEA5-4287-837B-B227FACE3215Q24241855-2C9F05A4-7111-4506-B3CF-717C8E5C1F6BQ24242844-E8D69F24-7F56-4F78-BD1D-AB2FB6370D1BQ24243771-A2A5F2B7-2308-424E-A9FB-C1B69E5DEF46Q24245066-FF4BFBBF-35A1-4763-8F4B-8E71F8515D2BQ24649148-3035BBDC-68A3-4DD7-ADD1-40AA0E0F3A20Q28769285-A154B8D7-734F-4992-93ED-96D2ACD0D809Q30486872-D687F015-1B5A-442D-8C09-4B8ADF73F237Q30746955-06194C99-D8D4-4B3A-90A4-84BB11D8CC99Q30832840-C90A336C-7A3D-4669-AF4E-AF2CB029464CQ31034999-B2840C23-C5D4-43D3-A531-E3EDDC3041D9Q33332278-879BE980-BD9C-48A2-A15E-9FF2EC835F02Q33701000-5E22157F-46B7-48C3-A308-135DDC34AD7BQ33708103-0E199127-FBCE-4D43-89D8-FB9EEC4236ECQ33722434-7FD8C229-BAC9-4CED-8178-F4D60C0A37A7Q33960335-5A5CBBF5-A757-4E22-9A8F-4E03C90353FAQ34003302-3DDF2C13-7785-4BF2-B92D-F72B24FA9A8EQ34555063-D08242EA-3CF5-4313-BAC9-4A9DA2841ECCQ34982100-C50FDDE2-652C-447F-B05F-7C4C16519D30Q35584135-AA8281CB-7D6A-41ED-9B62-02F426505A80Q35648850-4670305D-9DE9-49D1-BE4E-D5B0AF486578Q35683406-F18064F4-1B44-42C2-AAD3-FA042BAE2E69Q35692127-DB86BD50-18E0-450C-91CB-15A8F7BBF8BBQ35832400-0C60299D-80F8-44A7-935A-A567A4210D34Q35992639-D9A5C7D8-E807-4F45-8B0F-A6025E7C0E25Q35994505-336F51B8-D7F5-4274-B0C7-6414A1837308Q36043600-EE325AF2-514F-4369-9D00-98C26990F9D6Q36047986-4BA5F27A-B7BE-422D-B89C-7BBA62A470F2Q36048002-F9C5392B-6C7E-4284-9997-0FFE1A5D6BD9Q36290466-AB42DB08-A0A2-4D4D-B7F3-D38DFF614A59Q36359826-C812CE15-30F3-46BA-BDFB-08DFC3B8319AQ36431395-553F6221-3C89-4BE1-B23D-572B7E8739D1Q36610042-2EA68620-52A9-45E8-A8BF-434B92ABD0A0Q36611886-A7290490-B0A0-4C7D-ABC0-3EEB1ED21506
P2860
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年学术文章
@wuu
1976年学术文章
@zh-cn
1976年学术文章
@zh-hans
1976年学术文章
@zh-my
1976年学术文章
@zh-sg
1976年學術文章
@yue
1976年學術文章
@zh
1976年學術文章
@zh-hant
name
Risk and prognostic factors in trophoblastic neoplasia.
@en
type
label
Risk and prognostic factors in trophoblastic neoplasia.
@en
prefLabel
Risk and prognostic factors in trophoblastic neoplasia.
@en
P1433
P1476
Risk and prognostic factors in trophoblastic neoplasia.
@en
P2093
Bagshawe KD
P2860
P304
P356
10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E
P407
P577
1976-09-01T00:00:00Z